Target antigen and plasma cell phenotype are critical factors for sensitivity to response-adapted daratumumab therapy.

Saved in:
Bibliographic Details
Title: Target antigen and plasma cell phenotype are critical factors for sensitivity to response-adapted daratumumab therapy.
Authors: Meads MB; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL., Zhao X; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL., Noyes D; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL., Sudalagunta PR; Department of Cancer Physiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL., Achille A; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL., Zhang C; Molecular Genomics Core Facility, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL., Canevarolo RR; Department of Cancer Physiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL., Silva M; Department of Cancer Physiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL., Magaletti D; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL., DeAvila D; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL., Toska S; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL., Oates A; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL., Lastorino D; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL., Idiaquez DW; Department of Pathology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL., Song J; Department of Pathology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL., Sansil SS; Cancer Pharmacokinetics and Pharmacodynamics Core, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL., Yoder SJ; Molecular Genomics Core Facility, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL., Grajales-Cruz AF; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL., Blue B; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL., Freeman CL; Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL., Kim J; Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL., Alsina M; Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL., Brayer J; Departments of Malignant Hematology and Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL., Silva AS; Department of Cancer Physiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL., Song X; Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL., Shain KH; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL., Baz R; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
Source: Blood [Blood] 2026 Jan 29; Vol. 147 (5), pp. 497-512.
Publication Type: Clinical Trial, Phase II; Journal Article
Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1528-0020
DOI:10.1182/blood.2025029921